|
1
|
El-Serag HB: Hepatocellular carcinoma:
Recent trends in the United States. Gastroenterology. 127(Suppl 1):
S27–S34. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mittal S and El-Serag HB: Epidemiology of
hepatocellular carcinoma: Consider the population. J Clin
Gastroenterol. 47(Suppl): S2–S6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu
CL and Wong J: Clinicopathologic features of long-term survivors
and disease-free survivors after resection of hepatocellular
carcinoma: A study of a prospective cohort. J Clin Oncol.
19:3037–3044. 2001.PubMed/NCBI
|
|
5
|
Roayaie S, Obeidat K, Sposito C, Mariani
L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M and
Mazzaferro V: Resection of hepatocellular cancer ≤2 cm: Results
from two Western centers. Hepatology. 57:1426–1435. 2013.
View Article : Google Scholar
|
|
6
|
Earl TM and Chapman WC: Hepatocellular
carcinoma: Resection versus transplantation. Semin Liver Dis.
33:282–292. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peng ZW, Lin XJ, Zhang YJ, Liang HH, Guo
RP, Shi M and Chen MS: Radiofrequency ablation versus hepatic
resection for the treatment of hepatocellular carcinomas 2 cm or
smaller: A retrospective comparative study. Radiology.
262:1022–1033. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ramakrishna G, Rastogi A, Trehanpati N,
Sen B, Khosla R and Sarin SK: From cirrhosis to hepatocellular
carcinoma: New molecular insights on inflammation and cellular
senescence. Liver Cancer. 2:367–383. 2013. View Article : Google Scholar
|
|
9
|
Zhao YJ, Ju Q and Li GC: Tumor markers for
hepatocellular carcinoma. Mol Clin Oncol. 1:593–598. 2013.
|
|
10
|
Timek DT, Shi J, Liu H and Lin F:
Arginase-1, HepPar-1, and Glypican-3 are the most effective panel
of markers in distinguishing hepatocellular carcinoma from
metastatic tumor on fine-needle aspiration specimens. Am J Clin
Pathol. 138:203–210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tomuleasa C, Soritau O, Rus-Ciuca D, Pop
T, Todea D, Mosteanu O, Pintea B, Foris V, Susman S, Kacsó G, et
al: Isolation and characterization of hepatic cancer cells with
stem-like properties from hepatocellular carcinoma. J
Gastrointestin Liver Dis. 19:61–67. 2010.PubMed/NCBI
|
|
12
|
Krings G, Ramachandran R, Jain D, Wu TT,
Yeh MM, Torbenson M and Kakar S: Immunohistochemical pitfalls and
the importance of glypican 3 and arginase in the diagnosis of
scirrhous hepatocellular carcinoma. Mod Pathol. 26:782–791. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shiran MS, Isa MR, Sherina MS, Rampal L,
Hairuszah I and Sabariah AR: The utility of hepatocyte paraffin 1
antibody in the immunohistological distinction of hepatocellular
carcinoma from cholangiocarcinoma and metastatic carcinoma. Malays
J Pathol. 28:87–92. 2006.
|
|
14
|
Pfeiffer E, Kegel V, Zeilinger K,
Hengstler JG, Nüssler AK, Seehofer D and Damm G: Featured Article:
Isolation, characterization, and cultivation of human hepatocytes
and non-parenchymal liver cells. Exp Biol Med (Maywood).
240:645–656. 2015. View Article : Google Scholar
|
|
15
|
Ihara A, Koizumi H, Hashizume R and
Uchikoshi T: Expression of epithelial cadherin and alpha- and
beta-catenins in nontumoral livers and hepatocellular carcinomas.
Hepatology. 23:1441–1447. 1996.PubMed/NCBI
|
|
16
|
Wands JR and Kim M: WNT/β-catenin
signaling and hepatocellular carcinoma. Hepatology. 60:452–454.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ho M and Kim H: Glypican-3: A new target
for cancer immunotherapy. Eur J Cancer. 47:333–338. 2011.
View Article : Google Scholar :
|
|
18
|
The International Consensus Group for
Hepatocellular Neoplasia. Pathologic diagnosis of early
hepatocellular carcinoma: A report of the international consensus
group for hepatocellular neoplasia. Hepatology. 49:658–664. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Capurro M, Martin T, Shi W and Filmus J:
Glypican-3 binds to Frizzled and plays a direct role in the
stimulation of canonical Wnt signaling. J Cell Sci. 127:1565–1575.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Capurro MI, Xiang YY, Lobe C and Filmus J:
Glypican-3 promotes the growth of hepatocellular carcinoma by
stimulating canonical Wnt signaling. Cancer Res. 65:6245–6254.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yao M, Wang L, Dong Z, Qian Q, Shi Y, Yu
D, Wang S, Zheng W and Yao D: Glypican-3 as an emerging molecular
target for hepatocellular carcinoma gene therapy. Tumour Biol.
35:5857–5868. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J and
Li J: Cancer stem/progenitor cells are highly enriched in
CD133+CD44+ population in hepatocellular
carcinoma. Int J Cancer. 126:2067–2078. 2010. View Article : Google Scholar
|
|
23
|
Endo K and Terada T: Protein expression of
CD44 (standard and variant isoforms) in hepatocellular carcinoma:
Relationships with tumor grade, clinicopathologic parameters, p53
expression, and patient survival. J Hepatol. 32:78–84. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Afify A, Purnell P and Nguyen L: Role of
CD44s and CD44v6 on human breast cancer cell adhesion, migration,
and invasion. Exp Mol Pathol. 86:95–100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xie Z, Choong PF, Poon LF, Zhou J, Khng J,
Jasinghe VJ, Palaniyandi S and Chen CS: Inhibition of CD44
expression in hepatocellular carcinoma cells enhances apoptosis,
chemosensitivity, and reduces tumorigenesis and invasion. Cancer
Chemother Pharmacol. 62:949–957. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Blaner WS, O'Byrne SM, Wongsiriroj N,
Kluwe J, D'Ambrosio DM, Jiang H, Schwabe RF, Hillman EM, Piantedosi
R and Libien J: Hepatic stellate cell lipid droplets: A specialized
lipid droplet for retinoid storage. Biochim Biophys Acta.
1791:467–473. 2009. View Article : Google Scholar :
|
|
27
|
Amann T, Bataille F, Spruss T, Mühlbauer
M, Gäbele E, Schölmerich J, Kiefer P, Bosserhoff AK and Hellerbrand
C: Activated hepatic stellate cells promote tumorigenicity of
hepatocellular carcinoma. Cancer Sci. 100:646–653. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu G, Jing Y, Kou X, Ye F, Gao L, Fan Q,
Yang Y, Zhao Q, Li R, Wu M, et al: Hepatic stellate cells secreted
hepatocyte growth factor contributes to the chemoresistance of
hepatocellular carcinoma. PLoS One. 8:e733122013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Geng ZM, Li QH, Li WZ, Zheng JB and Shah
V: Activated human hepatic stellate cells promote growth of human
hepatocellular carcinoma in a subcutaneous xenograft nude mouse
model. Cell Biochem Biophys. 70:337–347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gao D, Vela I, Sboner A, Iaquinta PJ,
Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora
VK, et al: Organoid cultures derived from patients with advanced
prostate cancer. Cell. 159:176–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liang Y, Shilagard T, Xiao SY, Snyder N,
Lau D, Cicalese L, Weiss H, Vargas G and Lemon SM: Visualizing
hepatitis C virus infections in human liver by two-photon
microscopy. Gastroenterology. 137:1448–1458. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sachs N and Clevers H: Organoid cultures
for the analysis of cancer phenotypes. Curr Opin Genet Dev.
24:68–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zittermann SI, Capurro MI, Shi W and
Filmus J: Soluble glypican 3 inhibits the growth of hepatocellular
carcinoma in vitro and in vivo. Int J Cancer. 126:1291–1301.
2010.
|
|
34
|
Sun CK, Chua MS, He J and So SK:
Suppression of glypican 3 inhibits growth of hepatocellular
carcinoma cells through up-regulation of TGF-β2. Neoplasia.
13:735–747. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gao W, Kim H, Feng M, Phung Y, Xavier CP,
Rubin JS and Ho M: Inactivation of Wnt signaling by a human
antibody that recognizes the heparan sulfate chains of glypican-3
for liver cancer therapy. Hepatology. 60:576–587. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu S, Li Y, Chen W, Zheng P, Liu T, He W,
Zhang J and Zeng X: Silencing glypican-3 expression induces
apoptosis in human hepatocellular carcinoma cells. Biochem Biophys
Res Commun. 419:656–661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stock P, Brückner S, Ebensing S, Hempel M,
Dollinger MM and Christ B: The generation of hepatocytes from
mesenchymal stem cells and engraftment into murine liver. Nat
Protoc. 5:617–627. 2010. View Article : Google Scholar : PubMed/NCBI
|
